Victrex (LSE:VCT), the maker of high-performance PEEK polymers used in aerospace, medical and industrial applications, held its full-year profit guidance unchanged after third-quarter revenues climbed 18% against the same period a year earlier, driven by a 17% rise in sales volumes.
The third quarter, covering the three months to 30 June, extended momentum from the second quarter, with Aerospace and Electronics the primary growth engines, partly aided by a weak prior-year comparator in Aerospace following industry supply chain backlogs in 2025.
Medical showed some stabilisation, while average selling price held steady at £68 per kilogram.
For the nine months to 30 June, group revenue rose 7% to £231.6m on volumes up 10% to 3,375 tonnes.
Chief Executive James Routh said Q3 "maintained the positive momentum" from the second quarter, while flagging that normal seasonality and broader macroeconomic conditions, including potential implications for global demand and energy costs, remain considerations in the final quarter.
The board reiterated its expectation that full-year 2026 underlying pre-tax profit will fall in the range of £42m to £44m.
On its restructuring programme, Victrex said a headcount reduction of approximately 10% is largely complete, with most affected employees having left during the third quarter; annualised cost savings of at least £10m are on track but will be fully realised in fiscal 2027.
The group will host a Capital Markets Event in London on 24 September.
